Exhibits calcium-dependent phospholipase A2 activity. Involved in phospholipid metabolic process. Localizes to perinuclear region of cytoplasm and secretory granule. Human ortholog(s) of this gene implicated in cholecystolithiasis; colorectal cancer; gastroesophageal reflux disease; and human immunodeficiency virus infectious disease. Orthologous to human PLA2G2A (phospholipase A2 group IIA); PARTICIPATES IN glypican signaling pathway; indometacin pharmacodynamics pathway; indometacin pharmacodynamics pathway; INTERACTS WITH 17beta-estradiol; 17beta-estradiol 3-benzoate; 2,3,7,8-tetrachlorodibenzodioxine.
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA], IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of PLA2G2A mRNA
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one promotes the reaction [IFNG protein promotes the reaction [Decitabine results in increased expression of PLA2G2A protein]] more ...
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA], IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of PLA2G2A mRNA
Glucosamine inhibits the reaction [IL1B results in increased expression of PLA2G2A mRNA], IL1B inhibits the reaction [Glucosamine results in decreased expression of PLA2G2A mRNA]
BQ 788 inhibits the reaction [EDN3 protein inhibits the reaction [PLA2G2A protein affects the uptake of Calcium]], EDN3 protein inhibits the reaction [PLA2G2A protein affects the uptake of Calcium]
BQ 788 inhibits the reaction [EDN3 protein inhibits the reaction [PLA2G2A protein affects the uptake of Calcium]], EDN3 protein inhibits the reaction [PLA2G2A protein affects the uptake of Calcium]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of PLA2G2A mRNA
Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of PLA2G2A mRNA], Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of PLA2G2A protein]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of PLA2G2A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of PLA2G2A mRNA
[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of PLA2G2A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of PLA2G2A mRNA
caffeic acid phenethyl ester inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]]
Tetradecanoylphorbol Acetate inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]]
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of PLA2G2A mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of PLA2G2A mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of PLA2G2A mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
hydolyzes the acyl group at the sn-2 position of phospholipids present in lipoproteins and cell membranes forming non-esterified fatty acids and lysophospholipids
mRNA and cellular and extracellular protein levels were stimulated by interleukin-1beta (IL-1b) in cardiomyocytes; extracellular activity was also enhanced 70-fold
distal region bearing a CAAT/enhancer binding protein (C/EBP)-responsive element (-242 to -223) was sufficient for cAMP/protein kinase A-mediated promoter activation and the activation of the promoter by IL-1b requires activation of an Ets-responsive elem